Loss widens sharply. Monte Rosa Therapeutics reported a loss of $0.55 per share for Q4 2025, wider than the consensus estimate of a $0.34 loss. The loss widened by 63.4% versus expectations, marking a significant miss for the clinical-stage biotech. The company posted a net loss of $46.1 million for the quarter.
Revenue falls short. Q4 revenue came in at $2.8 million, missing the analyst consensus of $5.3 million by 47.3%. The top line declined sharply from Q1 2025’s $84.9 million and Q2 2025’s $23.2 million, reflecting the lumpy nature of collaboration revenue typical for early-stage biotechnology companies. The revenue miss compounds the earnings disappointment, suggesting potential delays in milestone payments or partnership activity.
Analyst support remains intact. Despite the wider-than-expected loss, the Street maintains unanimous bullish conviction with 8 Buy or Strong Buy ratings and zero Hold or Sell recommendations. This suggests analysts view the quarter’s shortfall as a timing issue rather than a fundamental setback. The stock trades at $16.02 with a market cap of $1.25 billion.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.